Clinical Trials Logo
  1. Home
  2. Non-Small Cell Lung Cancer
  3. NCT03427541
  4. Details
NCT03427541 Clinical Trial

A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases

Non Small Cell Lung Cancer Clinical Trial

Official title:
A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03427541
Other study ID # WTONG05
Secondary ID
Status Recruiting
Phase N/A
First received February 2, 2018
Last updated February 7, 2018
Start date December 31, 2017
Est. completion date April 30, 2018

Study information
Verified date February 2018
Source Tang-Du Hospital
Contact Haiying Yang, PhD
Phone 0086-010-62680809
Email celineyang@linkdoc.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases

Description:

A multi-centre real-world non-interventional observational study to explore prognoses and clinical treatments of the patients with non-small lung cancer complicated with oligometastases

Recruitment information / eligibility
Status Recruiting
Enrollment 1000
Est. completion date April 30, 2018
Est. primary completion date April 30, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Pathologically diagnosed patients with non-small cell lung cancer;

- Tumor metastases in one organ (no more than 3 metastases);

Exclusion Criteria:

- Patients with intrapulmonary metastases or multiple primary tumors;

- Patients with pleural dissemination or invasion of extrapulmonary organs;

- Patients with supraclavicular lymph node metastasis;

- Patients with systematic diseases that would influence patient survivals;

- Patients with no records for visits;

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Surgeries
Surgeries

Locations
Country Name City State
China China PLA General Hospital Beijing Beijing
China China-Japan Friendship Hospital Beijing Beijing
China Huaxi Hospital Affiliated to Sichuan University Chengdu Sichuan
China First Hospital Affiliated to Zhejiang University Hangzhou Zhejiang
China Jiangsu cancer hospital Nanjing Jiangsu
China Shanghai Chest Hospital Shanghai Shanghai
China Tianjin Chest Hospital Tianjin Tianjin
China Tongji Hospital Affiliated to Huazhong Technology Hospital Wuhan Hubei
China Xi'an Tangdu Hospital Xi'an Shaanxi
China Henan cancer hospital Zhengzhou Henan

Sponsors (2)
Lead Sponsor Collaborator
Tang-Du Hospital LinkDoc Technology (Beijing) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival Overall survival 2014 - 2017
Secondary Disease-free survival Disease-free survival 2014 - 2017
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1